Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin for Spasticity in Cerebral Palsy
NCT00133861Phase 3Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Apr 2005
- Primary completion
- Jun 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of neuronox in cerebral palsy (CP) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Passive Range of Motion at 6 months. Started Apr 2005; status: completed.
02
Drugs
neuronox
03
Conditions
cerebral palsy (CP)
Beyond the preview
Go deeper on NCT00133861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133861.